Introduction {#sec1}
============

The diplomonadid *Giardia lamblia* (syn. *G. duodenalis*, *G. intestinalis*), an early diverging, anaerobic eukaryote (Adam, [@ref1]; Cernikova *et al*., [@ref12]), is a causative agent of persistent diarrhoea widespread in regions with low hygienic standards (Hemphill *et al*., [@ref23]). After stomach passage, cysts ingested *via* contaminated food or water or *via* direct personal contact transform into trophozoites which colonize the duodenum and cause the symptoms peaking around 1 week post infection. In general, hosts in good physical condition recover within 2--3 weeks. In rare cases, the infection persists and becomes chronical causing severe damage of the intestinal epithelium (Allain *et al*., [@ref4]) occasionally resulting in the development of irritable bowel syndrome (Litleskare *et al*., [@ref26]). Eight different genotypes or assemblages, labelled A to H, have been identified, assemblages A and B having the broadest spectrum identifying animals as well as humans (Heyworth, [@ref24]). Furthermore, assemblage E isolates may cause human giardiasis, as well (Zahedi *et al*., [@ref61]). Thus, giardiasis occurs in humans as well as in other mammals and can be regarded as a zoonosis (Thompson, [@ref57]). Human giardiasis is treated with the nitroimidazole metronidazole as first-line and the benzimidazole albendazole as second-line drug. Quinacrine, one of the first antigiardial drugs, is not in use, anymore (Gardner and Hill, [@ref20]; Nash, [@ref39]).

The largest part of laboratory research is based on the strain WBC6, an assemblage A1 strain obtained by limited dilution cloning from the WB isolate obtained from duodenal contents from a patient suffering from chronical giardiasis refractory to either quinacrine or metronidazole (MET) treatments (Smith *et al*., [@ref54]). The isolate originates from Afghanistan (Smith *et al*., [@ref53]) and was axenized at the NIH (Nash *et al*., [@ref42]). The WBC6 strain, cloned by F. Gillin *via* limited dilution in 1983 (Campbell and Faubert, [@ref10]), eagerly produces cysts *in vitro* (Campbell and Faubert, [@ref10]), is amenable to genetic manipulation (Furfine and Wang, [@ref19]; Sun *et al*., [@ref55]), and its growth *in vitro* is less affected by the culture medium composition than other strains (own observations, see 'Materials and methods' section). Consequently, WBC6 is extensively used to investigate intracellular processes associated with en- and excystation of the parasite (Faso and Hehl, [@ref18]; Zamponi *et al*., [@ref62]) and has been the first *Giardia* strain where the complete genome has been sequenced (Morrison *et al*., [@ref29]). Unfortunately, in many articles before this hallmark, the strain is referred to as WB only. This is insofar confusing, as other clones from the same original isolate with distinct characteristics exist. The most striking of these characteristics is related to a unique feature of *G. lamblia*, namely antigenic variation (Nash, [@ref40]; Adam *et al*., [@ref3]). The genome of WBC6 and of other strains that have been sequenced so far (see [www.giardiadb.org](www.giardiadb.org)) contain several hundred open reading frames (ORFs) encoding the so-called variant-specific surface proteins (VSPs). According to a recently published chromosome-scale reference genome, the genes encoding for VSPs, as well as other highly repetitive genes, are distributed over all five chromosomes (Xu *et al*., [@ref59]). VSPs have the following properties in common: a signal peptide targeting the protein to the surface, a highly variable N-terminus with frequent CXXC-motifs (where X may be any amino acid), a nearly invariant C-terminus of 38 amino acids containing a CRGKA motif, a hydrophobic domain forming the membrane anchor (Adam *et al*., [@ref3]). The N-terminus of VSPs is highly immunogenic. VSPs therefore constitute the main surface antigens of *G. lamblia* trophozoites. According to a generally admitted hypothesis, one single trophozoite expresses only one VSP at the same time (Nash *et al*., [@ref45], [@ref47]). During encystation, however, several VSPs may be expressed by the same cell (Carranza *et al*., [@ref11]). The switching from one VSP to another, thus antigenic variation, at least indirectly depends in all likelihood, on posttranscriptional mechanisms (Kulakova *et al*., [@ref25]; Prucca *et al*., [@ref51], [@ref52]; Prucca and Lujan, [@ref50]).

Studies in the 80s and 90s based on monoclonal antibodies raised against specific epitopes revealed the presence of major VSPs in a given WB trophozoite population. A well-characterized member of these major surface antigens is VSPA6 (in the literature also referred to as CRP170 due to approximate size of 170 kDa) that is expressed by several subclones of the WB isolate (Adam *et al*., [@ref2]). VSPA6 is recognized by the cytotoxic monoclonal antibody (mAb) 6E7. Trophozoites resistant to mAb 6E7 express a different pattern of VSPs (Nash *et al*., [@ref43]). Even in the absence of this selective pressure, other VSPs recognized by different monoclonal antibodies appear after many generations (Nash *et al*., [@ref44]).

According to further studies, mAb 6E7 recognizes an octapeptide motif (GAAPLYKK) present in 65 amino acid repeats distributed in different numbers over the VSP primary sequence (Mowatt *et al*., [@ref30]) suggesting an evolution by gene duplication (Yang and Adam, [@ref60]).

Conversely, trophozoites of WBC6 express a predominant VSP, named TSA417, exhibiting a peptide molecular mass of 72.5 kDa as predicted by the corresponding gene sequence (Gillin *et al*., [@ref21]). Complement-dependent killing of trophozoites during exposure to anti-recombinant TSA417 antiserum provides a selective advantage for minor populations of non-TSA417-expressing trophozoites already present in the original culture (Meng *et al*., [@ref28]). Furthermore, WBC6 trophozoites bearing non-TSA417-type VSPs appear during the process of excystation (Meng *et al*., [@ref28]; Svärd *et al*., [@ref56]).

Another extensively studied *G. lamblia* strain, namely clone GS/M-83-H7, representing an assemblage B genotype, originates from the human isolate GS obtained in Alaska and axenized by isolation of trophozoites from infected neonatal mice (Nash *et al*., [@ref42]). This clone expresses a major surface antigen, VSP H7, which is immuno-reactive to a specific, cytotoxic mAb (mAb G10/4). VSP H7 has an apparent molecular mass of ca. 57 kDa (Nash and Mowatt, [@ref41]). For GS/M-83-H7, *in vitro* antigenic variation replacing VSP H7 by diverse other VSPs on the surface of trophozoites occurs at about one variation event per 6.5 generations in comparison to one variation event per 12--13 generations in the original WB isolate (Nash *et al*., [@ref44]). Since GS/M-83-H7 infects humans as well as mice, immune responses to VSP H7 have been investigated not only *in vitro* (Müller *et al*., [@ref34]) but also in mouse models (Gottstein *et al*., [@ref22]; Müller and Gottstein, [@ref31]). These studies show that antigenic variation occurs *in vivo* as a reaction to humoral immune responses in both hosts (Nash *et al*., [@ref46]; Bienz *et al*., [@ref6]; Müller and von Allmen, [@ref33]).

Recent shotgun mass spectrometry proteome studies have revealed that WBC6 trophozoite populations and trophozoite populations from other assemblage A strains express an impressive number of VSPs at the same time (Emery *et al*., [@ref15], [@ref16]). Other studies have revealed that strain-dependent antigenic diversification of trophozoites occurs upon selective drug pressure (Emery *et al*., [@ref17]; Emery-Corbin *et al*., [@ref14]; Müller *et al*., [@ref38]).

Using this sensitive method, we compared the well-characterized strain WBC6 with another clone of the parent WB isolate in the following termed WBA1. This clone grows only in a culture medium with strictly defined components and is refractory to antigenic variation, as previously shown (Nash *et al*., [@ref44]), and according to our own observations. Moreover, this strain is refractory to encystation (Campbell and Faubert, [@ref10]). We included the strain GS/M-83-H7 as an outgroup into our comparison expecting that more proteins are differentially expressed between this clone and either WB clone than between both WB clones. We were particularly interested in the expression levels of the predominant VSPs in each clone and matched the previously described major VSPs of each strain to the corresponding ORF sequences identified by whole-genome sequencing efforts. Furthermore, since the original WB isolate comes from a patient treated with the nitroimidazole metronidazole, and since antigenic variation has been shown to be influenced by drug exposure (Müller *et al*., [@ref38]), we compared the susceptibilities of the strains to nitro compounds and had a closer look on enzymes involved in nitro reduction and on the corresponding enzyme activities.

Materials and methods {#sec2}
=====================

Chemicals {#sec2-1}
---------

If not otherwise stated, all biochemical reagents were from Sigma (St Louis, MO, USA). Nitazoxanide (NTZ) was synthesized at the Department of Chemistry and Biochemistry, University of Bern, Switzerland (Ch. Leumann). NTZ, albendazole (ALB) and MET were kept as 100 m[m]{.smallcaps} stock solutions in DMSO at −20°C.

Axenic culture, harvest and storage of *G. lamblia* trophozoites {#sec2-2}
----------------------------------------------------------------

Trophozoites from *G. lamblia* WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were grown under anaerobic conditions in 10 mL culture tubes (Nunc, Roskilde, Denmark) on modified TYI-S-33 medium as previously described (Clark and Diamond, 2002). In order to ensure the growth of the A1 and H7 clones, the components were as close as possible to the isolation medium, in particular heat-inactivated adult bovine serum (Biofluids, Rockville, MD, USA) and casein peptone (Becton Dickinson, Cockeysville, MD, USA). Prior to shotgun mass spectrometry analysis, the cultures were routinely passaged two times. Subcultures were performed by inoculating 100 *μ*L of cells from a confluent culture detached by cooling (see below) to a new tube containing 10 mL culture medium (Müller *et al*., 2006). Trophozoites were harvested by incubation on ice for 15 min followed by centrifugation (300 × g, 10 min, 4°C). Pellets were washed three times with ice-cold PBS, counted and stored at −80°C for subsequent proteomic analysis or for enzymatic assays.

Proteomics {#sec2-3}
----------

Cell pellets were lysed in 100 *μ*L 8 [m]{.smallcaps} urea/100 m[m]{.smallcaps} Tris/HCl pH 8/cOmplete^TM^ protease inhibitor cocktail (Roche Diagnostics, Rotkreuz, Switzerland) by incubation for 15 min at room temperature followed by 15 min in an ultrasonic water bath. Proteins were reduced and alkylated with 10 m[m]{.smallcaps} DTT for 30 min at 37°C and 50 m[m]{.smallcaps} iodoacetamide for 30 min at 37°C. Proteins were precipitated at −20°C by addition of 5 volumes cold acetone and incubation at −20°C overnight. All liquid was carefully removed and the pellet dried in ambient air for 15 min before reconstitution of proteins in 200 *μ*L of 8 [m]{.smallcaps} urea, 50 m[m]{.smallcaps} Tris-HCl pH 8.0. Protein concentration was determined by Bradford assay and an aliquot corresponding to 10 *μ*g protein was digested by trypsin (1:50 trypsin/protein ratio) for 6 h at 37°C after dilution of urea concentration to 1.6 [m]{.smallcaps} with 20 m[m]{.smallcaps} Tris-HCl pH 8.0 and 2 m[m]{.smallcaps} CaCl2. The digests were acidified with TFA (1%) and analysed by LC-MS/MS. Three repetitive injections of an aliquot corresponding to 500 ng protein digest was separated on an EASY-nLC 1000 coupled to a QExactive mass spectrometer (ThermoFisher Scientific). Peptides were trapped on an Acclaim PepMap100 C18 pre-column (3 *μ*[m]{.smallcaps}, 100 A˚, 75 *μ*[m]{.smallcaps} × 2 cm, ThermoFisher Scientific, Reinach, Switzerland) and separated by backflush on a C18 column (3 *μ*[m]{.smallcaps}, 100 A˚, 75 *μ*[m]{.smallcaps} × 15 cm, Nikkyo Technos, Tokyo, Japan) by applying a 60 min gradient of 5% acetonitrile to 40% in water, 0.1% formic acid, at a flow rate of 400 nL min^−1^. Peptides of m/z 360--1400 were detected with a resolution of 70 000 applying an automatic gain control (AGC) target of 1E06 and a maximum ion injection time of 50 ms. A top 10 data-dependent method for precursor ion fragmentation with a stepped 27% normalized collision energy was applied with the following settings: precursor isolation width of 2 m/z, resolution 17 500, AGC of 1E05 with a minimum target of 1E03, maximum ion time of 110 ms, charge exclusion of unassigned and 1+ ions, peptide match on and dynamic exclusion for 20 s, respectively.

The MS data were obtained from three biological replicates, with three technical replicates for each biological replicate, for each strain. All MS data were processed by MaxQuant (version 1.5.4.1) with matching between runs for the same strain activated, but not between different strains, in order to avoid over-interpretation of the data. The sample sets were interpreted separately by MaxQuant. Fragment spectra were interpreted against a recent *Giardia* protein sequence database including both WB and GS datasets in fasta format (GiardiaDB-5.0_GintestinalisAssemblageA_AnnotatedProteins; GiardiaDB-5.0_GintestinalisAssemblageB_AnnotatedProteins_v2). The trypsin cleavage rule allowed amide bond cleavage after lysine and arginine but not if a proline follows and up to three missed cleavage sites, fixed carbamidomethylation modification of cysteines, variable oxidation of methionine and acetylation of protein N-termini. Precursor and fragment mass tolerances were set to 10 and 20 ppm, respectively. Peptide spectrum matches, peptide and protein group identifications were filtered to a 1% false discovery rate (FDR) based on reversed database sequence matches, and a minimum of two razor or unique peptides were required to accept a protein group identification. Protein identifications considered as contaminations (e.g. trypsin or BSA) as well as proteins identified only by site (considered by MaxQuant developers as very likely false positives) were removed for statistical validation. The normalized label-free quantification (LFQ) protein group intensities as calculated by MaxQuant were used for relative proteome quantifications. First, we imputed missing protein LFQ values for samples in any condition group when there were at least two LFQ intensities in one group (downshift of 2.5 [s.d.]{.smallcaps} with a width of 0.3 [s.d.]{.smallcaps}). When comparing VSPs only, peptides unique to a single VSP protein were used for the calculation of protein intensities based on the sum of the three most intense peptides (Top3 approach). Before summing, missing peptide intensities were imputed sample group wise, when there were at least two valid intensities (downshift of 1.8 [s.d.]{.smallcaps} with a width of 0.3 [s.d.]{.smallcaps}). The resulting protein intensities were named iTop3. This process left proteins without values in one or the other group. For Welch\'s *t*-tests, those missing protein intensities were replaced by imputed values from the very low end of intensity distributions in analogy to the LFQ imputation (downshift 2.5 [s.d.]{.smallcaps}, width of 0.3 [s.d.]{.smallcaps}). An FDR-controlled Benjamini--Hochberg procedure was used for the correction of *P* values. A log2-fold change of at least one and a corrected *P* value of 0.05 were required to be considered as significant. Statistical testing and imputation were made with a home-made R script run under R-Studio. Our main goal was to identify the VSPs in the H7 proteome. To do this, we had to use the assemblage B database. Since most of the other proteins share high homologies with those from assemblage A strains and are found in both databases, they are called orthologues. We eliminated those proteins that were expressed in both strains sharing the same ORF numbers (e.g. GL50803_10167 in assemblage A and GSB_10167 in assemblage B) *via* the GenesbyOrthologues tool on the GiardiaDB site ([www.giardiabd.org](www.giardiabd.org)). Small differences in peptide sequences or SNPs were not considered. They can easily be identified by comparing the sequences of orthologues provided by GiardiaDB. For comparative quantification of orthologues, the LFQ values corresponding to GL50803 were used for assemblage A strains and the values corresponding to GSB were used for assemblage B strains.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium *via* the PRIDE (Perez-Riverol *et al*., [@ref48]) partner repository with the dataset identifier PXD017597.

Drug susceptibility assays {#sec2-4}
--------------------------

Drug susceptibility of *G. lamblia* trophozoites of the strains C6, A1 and H7 was tested in 96-well plates inoculated with 10^3^ trophozoites per well and MET, NTZ or ALB at various concentrations (dilution factor 2) and incubated in an anaerobic growth chamber (85% N~2~, 10% H~2~, 5% CO~2~). After 72 h (C6, A1) or 96 h (H7), growth of cells was monitored by a vitality assay based on the reduction of resazurin (Alamar Blue) to a pink product that was assayed fluorimetrically (Bénéré *et al*., [@ref5]). The IC~50~ values were determined using the logit-log algorithm as described (Müller and Hemphill, [@ref32]).

To determine minimal inhibitory concentrations (MIC), WT and C4 trophozoites were inoculated in the presence of increasing amounts (dilution series by a factor 2) of the nitro compounds MET, NTZ or ALB as a control. The tubes were incubated at 37°C for 96 h (C6, A1) or 120 h (H7). The MIC was determined by observing the wells under the microscope starting from higher to lower concentrations. The concentration at which the first living trophozoites were visible is given as the MIC (Müller *et al*., [@ref37]).

Enzyme assays {#sec2-5}
-------------

Trophozoite crude extracts were prepared by suspending trophozoite pellets in 50 m[m]{.smallcaps} Tris-Cl^−^, pH 7.0, containing 0.05% triton-X-100 and a protease inhibitor mix (Halt, ThermoFisher Scientific, Waltham, MA) according to the manufacturer\'s instructions. NAD(P)H oxidase and quinone reductase activities were measured in 96-well microtiter plates containing 100 *μ*L of a reaction mix containing buffer (50 m[m]{.smallcaps} Tris-Cl^−^, pH 7.0), 0.5 m[m]{.smallcaps} thiazolyl blue tetrazolium (MTT), 0.5 m[m]{.smallcaps} NADH or NADPH and 5 *μ*L of crude extract. To measure quinone reductase activity, 0.1 m[m]{.smallcaps} menadione was added to the mix. The plates were incubated at 37°C under aerobic conditions. Substrate and enzyme blanks were included. After different time points, the reaction was stopped by adding 100 *μ*L of pure ethanol thus solubilizing the product formed by the reduction of MTT, formazan (Prochaska and Santamaria, [@ref49]; Müller *et al*., [@ref36]). Nitroreductase activity was quantified *via* the reduction of 7-nitrocoumarin (7-NC) to 7-aminocoumarin (7-AC) using the reaction mix as described above, without MTT and 0.1 m[m]{.smallcaps} 7-NC, with the same volumes and under the same conditions of incubation. Enzyme and substrate blanks were included. The reaction was stopped by adding 100 *μ*L of 50 m[m]{.smallcaps} HCl lowering the pH to allow full protonation of the reaction product (Wagner, [@ref58]). 7-AC was quantified by fluorimetry with excitation at 365 nm and emission at 455 nm (Müller *et al*., [@ref36]). Absorption at 590 nm (MTT-based assays) and fluorescence intensities were quantified using a 96-well multimode plate reader (Enspire; Perkin-Elmer, Waltham, MA, USA). Protein contents of crude extracts were determined by the Bradford method (Bradford, [@ref7]) using a commercial kit (Biorad, Hercules, CA, USA).

Results and discussion {#sec3}
======================

Mass spectrometry analysis of proteins expressed in *G. lamblia* trophozoites {#sec3-1}
-----------------------------------------------------------------------------

Shotgun mass spectrometry of the proteomes of trophozoites of the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) allowed the identification of 24 739 unique peptides matching to 2 368 proteins (Table S1). Overall analysis of the data by principal component analysis (PCA) revealed that biological and technical replicates clustered together for each strain. The proteomes of the three strains formed non-overlapping clusters. A1 and C6 were separated by PC2 only, whereas the proteome of H7 was separated by both other strains PC1 and PC2 ([Fig. 1](#fig01){ref-type="fig"}). A PCA with strains A1 and C6 only is shown in Fig. S1. Fig. 1.Principal component analysis of proteome dataset from *G. lamblia* trophozoites of different strains. Trophozoites of the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were compared by MS shotgun analysis as described in 'Materials and methods' section. For each strain, all technical and biological (square, circle, diamond) replicates are shown.

Differentially expressed proteins {#sec3-2}
---------------------------------

To get a better estimation of 'true' differentials between assemblage and B strains, orthologues present in both A and B strains have been subtracted using the GenesbyOrthologues function implemented in the GiardiaDB. Without eliminating these orthologues from the comparison, WBC6 *vs* H7 would yield 1320 differentials, WBA1 *vs* H7 would yield 1264 differentials. This analysis revealed that between strains C6 and A1, 97 proteins were differentially expressed, as compared to 454 proteins between strains C6 and H7 ([Fig. 2](#fig02){ref-type="fig"}). Comparison of differentially expressed proteins between the strains H7 *vs* the strains C6 and A1 revealed that 253 proteins had higher levels in both WB strains than in H7, and 146 proteins had higher levels in H7 than in the WB strains. Besides hypothetical proteins, the categories with the highest numbers of differentials comprised proteins involved in cytoskeleton, adhesion and organelle transport, intermediary metabolism, gene expression and development, and signalling ([Table 1](#tab01){ref-type="table"}). Strain H7 expressed a unique set of 13 VSPs different from the VSP sets expressed in both WB strains. H7 and the WB clones belong to different assemblages, it is not surprising that an order of magnitude more differential proteins are identified between H7 and the WB clones than between the two WB clones. Some of the proteins overexpressed in H7, in particular proteins involved in signalling or attachment, may contribute to the broad host spectrum of this strain, which infects humans as well as animals, as reviewed elsewhere (Müller and von Allmen, [@ref33]). Fig. 2.Venn diagram detailing the number of differentially expressed proteins in *G. lamblia* trophozoites of different strains. Trophozoites of the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were subjected to MS shotgun analysis as described in 'Materials and methods' section. Orthologues present in both A and B strains have been subtracted using the GenesbyOrthologues function implemented in the GiardiaDB. Table 1.Number of differentially expressed proteins in strain GS/M-83-H7 as compared to both WBC6 and WBA1 trophozoites(Hypothetical) functionHigher levels in WBC6 and WBA1Higher levels in GS/M-83-H7Variant-specific surface proteins413Cytoskeleton, adhesion and organelle transport3415Intermediary metabolism5422Signalling1613Gene expression, cell cycle, development4817Chaperones100Transport of metabolites95Hypothetical8260Total253145[^1]

When comparing the set of the 97 differentially expressed proteins between C6 and A1 in more detail, it turned out that -- besides 32 hypothetical proteins -- 22 VSPs differed between these strains. Eleven differential proteins were involved in signalling, 11 cytoskeleton-related proteins, 10 involved in intermediary metabolism, 10 proteins with functions in gene expression and development, and one with a chaperone-like function ([Table 2](#tab02){ref-type="table"}). Thirty-four proteins were also significantly lower in strain H7 as compared to C6 ([Fig. 2](#fig02){ref-type="fig"}), in particular the 15 C6-specific VSPs (see 'Antigenic variation' section) and 19 proteins with various functions, as highlighted in [Table 2](#tab02){ref-type="table"}. Table 2.Overview of ORFs differentially expressed in WBC6 (C6) as compared to WBA1 (A1) trophozoites(Hypothetical) functionProteinORF number in *Giardia* databaseHigher expression in C6Variant-specific surface proteins*VSP-88*101 074*VSP-169*112 801*VSP-44*113 450*VSP-5*113 797*VSP-149*116 477*VSP-38*13 194*VSP-160*137 612*VSP-188*137 613*VSP-77*137 617*VSP-8*137 618*VSP-3*137 740*VSP-186*14 586*VSP-100*33 279*VSP-49*41 472*VSP-121*5812Cytoskeleton, adhesion and organelle transportProtein 21.1101 168Ankyrin repeat protein14 745IFT complex B17 223Protein 21.1 (Ankyrin repeat)17 608*ENC6 protein*24 372Trichohyalin32 375Protein 21.13760*Cyst wall protein 2*5435*Synaptic glycoprotein SC2*88 581Dynein heavy chain94 440Intermediary metabolism*Ubiquitin carboxyl-terminal hydrolase 14*102 710Peroxiredoxin 114 5212,5-diketo-D-gluconic acid reductase151 884NAD(P)H:menadione oxidoreductase17 150Nitroreductase Fd-NR222 677L-serine dehydratase24 662Glucosamine-6-phosphate deaminase8245*Adenylate kinase*90 402SignallingKinase, AGC PKA11 214Kinase, NEK13 215Kinase, NEK137 733Kinase, CAMK CAMKL14 661*ARF GAP*17 561AMP-activated protein kinase, gamma-1 subunit3414Gene expression, cell cycle, developmentChromosome segregation protein SMC10 027Threonyl and alanyl tRNA synthetase second additional domain150 018CDC1917 413Golgi/cell cycle associated protein, putative17 472Preimplantation protein 33417SBDS C-terminal domain protein, putative40 521*Pelo protein*5892ChaperonesT-complex protein 1, *β* subunit11 397Hypothetical(25 proteins)*(12 proteins also in H7)*Higher expression in A1Variant-specific surface proteinsHigh cysteine membrane protein VSP-like112 135High cysteine membrane protein Group 111 309VSP-175137 608High cysteine membrane protein Group 116 318CXC-rich protein17 476VSP A6 (annotated as hypothetical protein)221 693High cysteine membrane protein Group 641 942Cytoskeleton, adhesion and organelle transportDynein heavy chain17 243Intermediary metabolismGlycosaminoglycan polysaccharide lyase10 238Nitroreductase family protein15 307SignallingKinase, NEK14 216Kinase, CAMK CAMKL17 566Serine/threonine protein phosphatase 521 498Protein kinase NEK family protein152 721Gene expression, cell cycle, developmentMCM215 344DNA replication licensing factor MCM617 390RNA binding protein, putative92 031Hypothetical(8 proteins)[^2]

Antigenic variation {#sec3-3}
-------------------

The strains investigated in this study had been characterized with respect to their (major) surface antigens. Therefore, in a first step, we matched the original antigens by protein--protein blasts to sequences found in the GiardiaDB. It turned out that sequences attributed to TSA417 (strain C6) matched to GL50803_113797, annotated as VSP5 and to GL50803_113450, annotated as VSP44. Concerning strain H7, the sequence published for VSPH7 matched to GSB150963.

Surprisingly, the sequence of CRP170, the predominant surface antigen of strain A1, matched to a sequence annotated as a hypothetical protein, namely GL50803_221693 with 100% identity and a total score of 3491 (Fig. S2). The GL50803_221693 ORF encodes a 228 kDa protein containing 2259 amino acids. The identified peptides of GL50803_221693 covered unique protein sequences near the N terminus (aa 75--151), followed by 26 repeats of the peptide TNPSDPTGTCVSAVDCQGSAGYYTDDS-VSDAKECKKCNAPCTACAGTADKCTKCDANGAAPYLKK (thus containing the GAAPYLKK motif recognized by mAb6E7), and a unique sequence near the C-terminus (aa 1812--2223). Regions where trypsin produces too long/hydrophobic or too short peptides, namely the two transmembrane helices at the C- and N-terminal part of the protein, were missed as can be expected by the used technology (Fig. S3). Proteins encoded by other ORFs sharing high score homologies with CRP170, namely GL50803_137752 and GL50803_37093 (Fig. S2), were not detected in the present dataset.

In a second step, we compared the LFQ intensities of the major VSPs in all strains ([Fig. 3](#fig03){ref-type="fig"}). In the case of strain C6, TSA417 (VSP5; ORF113797) was still one of the dominating VSPs, followed by VSP-8 (ORF 137618), VSP-188 (ORF 137613) and four other VSPs in the range of 10^7^ LFQ units ([Fig. 3A](#fig03){ref-type="fig"}). Amongst these VSPs were the gene products of ORFs 101074 and 137618. ORF 101074 (VSP88) was identical to the sequence of AAG16629, annotated as VSP9B10A (Nash *et al*., [@ref47]). ORF 137618 (VSP8) covered AF293416, annotated as VSPB10B (Carranza *et al*., [@ref11]) only to 88% leaving 70 amino acid gaps. In a previously published comparative proteomics study (Emery *et al*., [@ref16]), a strain WB expressed four of the major VSPs identified in WBC6, namely VSP38 (ORF 13194), VSP49 (ORF 41472), VSP149 (ORF 116477) and the previously mentioned VSP188. Fig. 3.Quantitative assessments of the major variant-specific surface proteins (VSPs). Trophozoites of the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were subjected to MS shotgun analysis as described in 'Materials and methods' section. For all VSPs, mean values ± one standard deviation for LFQ intensities (×10^6^) in three biological replicates are shown. The VSPs are termed by their respective accession numbers in the GiardiaDB (GL50803 for C6 and A1; GSB for H7). A, VSP pattern of strain C6; B, VSP pattern of strain A1; C, VSP pattern of strain H7.

In strain A1, GL50803_221693 (homologous to VSPA6) was -- by far -- the most predominant VSP with LFQ values above 10^11^, but not the only one identified. The five next abundant VSPs had, however, expression levels three or more magnitudes lower than VSPA6. Interestingly, VSPA6 was expressed in strain C6 as well, but only at LFQ levels below 10^7^ ([Fig. 3B](#fig03){ref-type="fig"}). In strain H7, 13 VSPs with LFQ levels around 10^7^ or higher were identified. VSPH7 (GSB150963) was not predominant, five other VSPs having equal or higher expression levels ([Fig. 3C](#fig03){ref-type="fig"}).

Moreover, we have reinvestigated the most predominant VSPs of the three strains using only peptides labelled as being unique to a single VSP by using iTop3 protein intensities (see 'Materials and methods' section and Table S2). The corresponding values are shown as Supplementary Fig. S4. Some minor VSPs disappeared, but the overall pattern of the strains did not change as compared to the analysis based on LFQ values.

These results show that A1 had the most 'homogeneous' population of trophozoites with respect to their surface proteome. The two other strains yielded mixed trophozoite populations with five or more equally dominant subpopulations.

The fact that VSPA6 was expressed at low levels in strain C6 prompted us to investigate whether this VSP was found in the proteome of the same strain grown on a different medium. The corresponding dataset had been published earlier in a different context (Müller *et al*., [@ref38]). Since the corresponding ORF (221693) was annotated as a hypothetical protein and not as a VSP, the corresponding expression levels had been overlooked. As shown in Table S3, VSPA6 became the third most abundant VSP in C6 trophozoites grown on a new culture medium differing from the old one merely with respect to the quality of the serum and the peptone. Moreover, VSPA6 had very high expression levels in two Australian assemblage A1 isolates investigated in the same study (Müller *et al*., [@ref38]). Thus, VSPA6 cannot be regarded as a unique marker for WBA1 and related clones.

Susceptibility to antigiardial drugs and reductase activities {#sec3-4}
-------------------------------------------------------------

Since the strains C6 and A1 had been isolated from a patient treated with MET, we were curious to investigate whether these strains differed in their susceptibilities to nitro drugs from the strain H7 isolated from a different source. Interestingly, strain A1 had higher IC~50~s than strain C6 when exposed to MET and to NTZ, but not to ALB. Strain H7 was more susceptible to MET and to ALB than both strains C6 and A1 ([Fig. 4](#fig04){ref-type="fig"}). The MIC of both nitro drugs were even nearly one order of magnitude higher on A1 than on both other strains ([Table 3](#tab03){ref-type="table"}). When comparing IC~50~s and MICs from different strains, one should consider that these constants measure different things, as reviewed elsewhere (Müller and Hemphill, [@ref32]). In the case of bacteria exposed to antibiotics, elevated MICs are regarded as indicative for 'resistance', whereas elevated IC~50~s without elevated MICs indicate 'tolerance' (Brauner *et al*., [@ref8]). In our case, strain A1 would be at the edge of 'resistance' with, however, much lower MICs than those of resistant strains generated in the laboratory (Müller *et al*., [@ref37]). Fig. 4.Determination of drug susceptibilities. The strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were exposed to serial dilutions of the nitro compounds metronidazole (MET) and nitazoxanide (NTZ), as well as of albendazole (ALB). IC~50~ values were determined as described in 'Materials and methods' section and are given in *μ*[m]{.smallcaps} (MET, NTZ) or nm (ALB). Diamonds correspond to the IC~50~s, bars to the 95% confidence intervals. Table 3.Determination of minimal inhibitory concentrations (MICs)CompoundC6A1H7MET6.25506.25NTZ1.25101.25ALB0.1250.1250.125[^3]

To see whether these differences matched to differences in reductase activities, we assayed NAD(P)H oxidase activity, quinone reductase activity and nitroreductase activity in crude extracts from the three strains ([Fig. 5](#fig05){ref-type="fig"}). Crude extracts from strains A1 and H7 had significantly lower NADPH oxidase, but not lower NADH oxidase activities than strain C6 ([Fig. 5A](#fig05){ref-type="fig"}). Quinone reductase activity with menadione as a substrate was at equal levels in crude extracts from all three strains ([Fig. 5B](#fig05){ref-type="fig"}). Nitroreductase activity, assayed as the full reduction of 7-NC to 7-AC was slightly, but significantly increased in A1 as compared to C6 crude extracts. Crude extracts from strain H7 had an intermediate activity ([Fig. 5C](#fig05){ref-type="fig"}). Fig. 5.Reductase activities in crude extracts of *G. lamblia* trophozoites. The assays were performed as described in 'Materials and methods' section using either NADH (white bars) or NADPH (black bars) as cofactors. A, NAD(P)H oxidase; B, quinone reductase with menadione as a substrate; C, nitroreductase with 7-nitrocoumarin as a substrate. Mean values ± one standard deviation for three independent assays are given. Values superscribed by different letters are significantly different (two-sided *t*-tests; *P* \< 0.05).

Enzymes involved in nitro reduction or detoxification processes {#sec3-5}
---------------------------------------------------------------

These findings prompted us to have a closer look at the expression levels of enzymes involved in nitro reduction and related detoxification processes. The values are listed in [Table 4](#tab04){ref-type="table"}. Strain C6 had significantly higher levels of the nitroreductase NR1 than the two other strains. Conversely, A1 was the only strain expressing the homologous NR family protein without ferredoxin domain at its N-terminus. C6 and A1, but not H7, expressed a 2Fe-2S ferredoxin, the only free ferredoxin detected in the proteome of the strains investigated in this study. Moreover, the ferredoxin-domain protein hydrogenase 1 was identified in all strains with significantly higher levels in strain H7. Table 4.Overview of proteins involved in reduction (and thus activation) of nitro compounds and the scavenging of radicals in trophozoites of the strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7)AnnotationDBC6A1H7Fd-NR2 ('NR1')22 677106 ± 5\*61 ± 162 ± 2Fd 2Fe_2S27 2669 ± 110 ± 0nd\*Fd-hydrogenase 1630446 ± 145 ± 0122 ± 9\*NR family ('NR3')15 307nd4 ± 0\*ndPFOR 117 0631713 ± 221510 ± 292290 ± 20PFOR 2114 6094619 ± 483966 ± 373938 ± 51Thioredoxin-reductase9827243 ± 26208 ± 20226 ± 7A-type flavoprotein10 358681 ± 11\*471 ± 10461 ± 13NAD(P)H oxidase lateral transfer33 7692324 ± 562103 ± 552032 ± 50NAD(P)H oxidase9719490 ± 16\*332 ± 11290 ± 3[^4]

C6 had significantly higher levels of A-type flavoprotein and of NAD(P)H oxidase than the two other strains. All other proteins investigated within this context, in particular both pyruvate-ferredoxin-oxidoreductases, did not differ between the strains ([Table 4](#tab04){ref-type="table"}).

Conclusions {#sec4}
===========

Our results, in particular those concerning the surface proteome of the investigated strains, show that care must be taken when referring to these strains using the VSP terminology established three decades ago as a result of their reactivity with monoclonal antibodies. A given antibody may cross-react with epitopes on VSPs encoded by a different ORF with high sequence identity and/or with VSPs carrying epitopes with a similar secondary structure, as illustrated by the following example. Using the monoclonal antibody Mab9B10, for instance, two different VSPs, namely VSP9B10A (Nash *et al*., [@ref47]) and VSP9B10B (Carranza *et al*., [@ref11]) were identified, which correspond to two major VSPs (VSP88 for sure and VSP8 most likely) of strain WBC6 as shown in our dataset.

Consequently, the hypothesis that one single trophozoite expresses one single VSP could be modified in the sense that one single trophozoite may express VSPs that may be encoded by one or more ORFs. This hypothesis could be verified only by single-cell proteomics (Dou *et al*., [@ref13]; Liu *et al*., [@ref27]), a method which has not been established for *G. lamblia*, so far.

Rich in potential trypsin and chymotrypsin cleavage sites inside a highly repetitive motif (covering three-quarters of its primary sequence in the case of VSPA6), the digest by pancreas proteases (or by proteases released by decaying trophozoites) may yield free epitopes blocking otherwise cytotoxic antibodies. Such a scenario may be relevant for the outcome of *G. lamblia* infections because cytotoxic anti-VSP antibodies turned out to possess a modulatory function on the proliferative parasite population characteristics in the experimental murine host as reviewed elsewhere (Müller and Gottstein, [@ref31]; Müller and von Allmen, [@ref33]). Moreover, VSPs may have enzymatic functions as evidenced in the case of VSP9B10A (ORF 101074; VSP88), which has cysteine protease activity (Cabrera-Licona *et al*., [@ref9]). Other functions such as enzyme activities or interactions with receptors on other trophozoites or on host cells remain to be elucidated.

Since the WB isolate issues from a patient treated with MET, the clones A1 and C6 may represent two different strategies to deal with this drug pressure. WBC6 retains a higher flexibility with respect to gene expression and is able to generate a highly nitro drug-resistant offspring in a few selection cycles (Müller *et al*., [@ref35]) differing from the original clone with respect to appropriate physiological adaptations and an adapted proteome (Müller *et al*., [@ref37]; Müller *et al*., [@ref38]). Conversely, WBA1 may represent a 'freezed' status with a moderate nitro drug resistance at the price of a loss in gene expression flexibility.

This hypothesis including the identification of elements controlling this flexibility, e.g. in the differential signalome of both strains as evidenced in our dataset, would require further investigations.

The *Giardia* strains used in this study were generous gifts by Bruno Gottstein and Theodore Nash.
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[^1]: The strains were grown and processed for MS shotgun analysis as described in 'Materials and methods' section. The proteins are grouped with respect to their hypothetical functions.

[^2]: The strains were grown and processed for MS shotgun analysis as described in 'Materials and methods' section. For each strain, three biological replicates have been tested (with three technical replicates per biological replicate). The proteins in this list had significantly different expression levels both in iLFQ and iTop3 values. The proteins with different expression levels also in strain GS/M-83-H7 are printed in italics.

[^3]: The strains WBC6 (C6), WBA1 (A1) and GS/M-83-H7 (H7) were exposed to serial dilutions of the nitro compounds metronidazole (MET) and nitazoxanide (NTZ), as well as of albendazole (ALB). MICs were determined as described in 'Materials and methods' section and are given in *μ*[m]{.smallcaps}.

[^4]: Cells were harvested and subjected to MS shotgun analysis as described in 'Materials and methods' section. For each strain, three biological replicates have been tested (with three technical replicates per biological replicate). For all proteins, mean values ± standard errors for LFQ intensities (×10^6^) in three biological replicates are given (nd, below detection limit). DB, number in GiardiaDB; Fd, ferredoxin; LT, lateral transfer; NR, nitroreductase; PFOR, pyruvate-ferredoxin oxidoreductase. \*, value is statistically significant from the two others (one-factorial ANOVA, *P* \< 0.01).
